MUSCLE STIMULATION DEVICES MARKET ANALYSIS

Muscle Stimulation Devices Market, by Product Type (Transcutaneous Electrical Nerve Stimulation (TENS), Interferential Current Electrical Stimulation (IFC), Burst Mode Alternating Current (BMAC), Neuromuscular Electrical Stimulation (NMES)), By Application (Pain Management, Neurological and Movement Disorder Management, Musculoskeletal Disorder Management), By End user (Hospitals, Physiotherapy Clinics, Sports Clinics, Home Care), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : May 2023
Code : CMI3518
Pages :177
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Global Muscle Stimulation Devices Market: Key Developments

In May 2021, ITO CO., LTD., is Japan-based engineering and manufacturers and electrophysical agents announced that electrical muscle stimulator for TMJ (temporomandibular joint) Pain Relief "D function" had received 510(k) clearance by the U.S. FDA. Its use for Prevents and reveres muscle atrophy (loss of muscle mass/tissue) Enhances rehabilitation of muscles. Increases range of motion for tense muscles or tendons. Reduces stress and discomfort.

In September 2021, NCS America, Inc., is a medical technology company announced that U.S. Food and Drug Administration (FDA) cleared the Shoulder Pacemaker and its unique Motion Activated Stimulation (MAS) technology. The Shoulder Pacemaker is an innovative wearable electro stimulator created for patients suffering from unbalanced muscle activation in the shoulder.

In October 2022, Medtronic is a medical technology, services, and solutions. The Company launched Medtronic Neurovascular Co-Lab Platform to accelerate innovation in stroke treatment. Neurovascular Co-Lab Platform drives collaboration and connections among start-ups, physicians, and institutions; aims to improve stroke treatment and access for patients worldwide.

In July 2021, Neurolief, an Israel-based neuromodulation company and NeuroFront, a clinical stage biotech company, announced an exclusive licensing agreement for NeuroFront to develop and commercialize Relivion, non-invasive medical devices for the treatment of migraine and depression, in China and South Korea.